Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Peptide Receptor Radionuclide Therapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT02736448
What this trial is testing

177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors

Who this might be right for
Gastro-entero-pancreatic Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 35
Testing effectiveness (Phase 2)Looking for participantsNCT04086485
What this trial is testing

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Who this might be right for
Gastroenteropancreatico TumorsNeuroendocrine TumorsNeuroendocrine Neoplasms
National Cancer Institute (NCI) 56
Not applicableStudy completedNCT05427032
What this trial is testing

HRQoL During PRRT in Patients With NETs

Who this might be right for
Neuroendocrine TumorsQuality of LifePeptide Receptor Radionuclide Therapy
Uppsala University 756
Large-scale testing (Phase 3)WithdrawnNCT01860742
What this trial is testing

Randomized Phase III of PRRT Versus Interferon

Who this might be right for
Gastro-intestinal Neuroendocrine Tumors
Jules Bordet Institute